Pure Global AI
NCT06208410Recruiting

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.Phase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
JS105
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Risen (Suzhou) Pharma Tech Co., Ltd.
Location
Zhengzhou, China
Timeline & enrollment
Phase
Phase 1/2
Start date
Jan 11, 2024
End date
Feb 26, 2026
Enrollment
306 participants
Primary outcome

Dose-limiting toxicity,MTD,RP2D,Incidence and severity of adverse events including serious adverse events

Summary

This study is an open-label, multicenter, Phase Ib/II clinical study to evaluate the safety,
 tolerability, pharmacokinetics, and preliminary efficacy of JS105 in combination with other
 anti-tumor therapies in patients with advanced solid tumors. Patients will be enrolled in two
 stages: a dose-escalation stage and a dose-expansion stage.

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06208410
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06208410 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Risen (Suzhou) Pharma Tech Co., Ltd. and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 306 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.